79 patents
Utility
Pyruvate kinase modulators and use thereof
16 Jan 24
Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
Filed: 27 Jan 22
Utility
Therapeutic compounds and compositions
9 Jan 24
Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein.
Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
Filed: 8 Mar 21
Utility
Compounds and Methods Useful for Stabilizing Phenylalanine Hydroxylase Mutations
16 Nov 23
Lucrezia De Pascalis, Heather Jane Finlay, Sandra King, Zenon D. Konteatis, Brian C. Shook
Filed: 27 Feb 23
Utility
Compounds and Methods Useful for Stabilizing Phenylalanine Hydroxylase Mutations
26 Oct 23
Lucrezia De Pascalis, Heather Jane Finlay, Sandra King, Zenon D. Konteatis, Brian C. Shook
Filed: 27 Jun 23
Utility
Pharmaceutical Formulation
26 Oct 23
Disclosed is a pharmaceutical mini-tablet comprising mitapivat or a pharmaceutically acceptable salt thereof, and in a particular embodiment comprising a mitapivat sulfate salt, and one or more inactive ingredients selected from a filler, disintegrant, lubricant, binder, and diluent.
Cheuk-Yui Leung, Eric Simone, Ophelia Qiping Yin
Filed: 24 Sep 21
Utility
Pyruvate kinase activators for use in therapy
24 Oct 23
Described herein are methods for using compounds that activate pyruvate kinase.
Shin-San Michael Su, Lenny Dang
Filed: 2 Apr 21
Utility
Pyruvate Kinase Activators for Use In Treating Blood Disorders
20 Jul 23
Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
Filed: 20 Jan 23
Reissue
Therapeutic compounds and compositions
18 Jul 23
Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein.
Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
Filed: 22 Dec 20
Utility
Pyruvate kinase activators for use in treating blood disorders
28 Feb 23
Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
Filed: 15 Aug 18
Utility
Pyruvate Kinase Activators for Use In Treating Blood Disorders
15 Dec 22
Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
Filed: 16 May 22
Utility
Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
13 Dec 22
Zenon D. Konteatis, Mingzong Li, Peng Liu, Matthew Medeiros, Samuel K. Reznik, Zhihua Sui, Jeremy M. Travins, Janeta Popovici-Muller, Shubao Zhou, Guangning Ma
Filed: 28 Mar 19
Utility
Therapeutically active compounds and their methods of use
22 Nov 22
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
Filed: 18 Jun 20
Utility
Therapeutically Active Compounds and Their Methods of Use
10 Nov 22
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Zenon Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
Filed: 26 Jan 21
Utility
Therapeutically Active Compounds and Their Methods of Use
3 Nov 22
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
Filed: 18 Jun 20
Utility
Pyruvate kinase modulators and use thereof
11 Oct 22
Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
Filed: 15 Aug 18
Utility
Methods of treating brain tumors using combination therapy
4 Oct 22
Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
Joshua Murtie, Nelamangala Nagaraja, Brandon Nicolay, David Schenkein, Katharine Yen
Filed: 12 Jun 18
Utility
Pyruvate Kinase Modulators and Use Thereof
28 Jul 22
Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
Filed: 27 Jan 22
Utility
Tablet compositions
19 Jul 22
Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.
Sreenivas S. Bhat, Scott Burnside, Darshan Parikh, Chong-Hui Gu, Syed Altaf
Filed: 6 Sep 17
Utility
Crystalline Forms of N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
14 Jul 22
Jacob P. Sizemore, Liting Guo, Mahmoud Mirmehrabi, Yeqing Su
Filed: 14 Jan 22
Utility
Pyruvate kinase activators for use in treating blood disorders
21 Jun 22
Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
Filed: 15 Aug 18